SpringWorks Therapeutics (SWTX) Expected to Announce Quarterly Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) is projected to release its earnings data before the market opens on Thursday, February 20th. Analysts expect SpringWorks Therapeutics to post earnings of ($0.66) per share and revenue of $60.53 million for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

SpringWorks Therapeutics Price Performance

NASDAQ SWTX traded down $1.43 during trading hours on Tuesday, reaching $56.00. 1,180,031 shares of the company's stock traded hands, compared to its average volume of 2,560,919. SpringWorks Therapeutics has a 52-week low of $28.21 and a 52-week high of $60.00. The firm has a 50-day simple moving average of $39.66 and a 200 day simple moving average of $37.02. The firm has a market cap of $4.17 billion, a PE ratio of -14.45 and a beta of 0.81.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Guggenheim decreased their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. Wedbush reaffirmed an "outperform" rating and set a $77.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday, February 10th. HC Wainwright restated a "buy" rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a research report on Wednesday, February 12th. Finally, Evercore ISI lifted their target price on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $70.83.

Insider Activity at SpringWorks Therapeutics

In other news, CEO Saqib Islam sold 48,000 shares of the firm's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $53.30, for a total value of $2,558,400.00. Following the completion of the sale, the chief executive officer now owns 1,002,502 shares of the company's stock, valued at $53,433,356.60. This trade represents a 4.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Badreddin Edris sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $41.97, for a total transaction of $839,400.00. Following the transaction, the chief operating officer now owns 209,600 shares in the company, valued at $8,796,912. The trade was a 8.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 302,750 shares of company stock valued at $16,139,410 over the last ninety days. 7.61% of the stock is owned by company insiders.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.